BETHLEHEM, Pa., May 3, 2013 /PRNewswire/ -- Supporting consistent federal oversight of sterile compounding in the United States, Central Admixture Pharmacy Services, Inc. (CAPS®), a B. Braun company, submitted its comments today to the U.S. Senate Committee on Health, Education, Labor, and Pensions (HELP) regarding the committee's draft legislation on sterile compounding.
"We strongly believe that consistency will be the key," said Mike Koch , CAPS Vice President, Marketing and Support Services. "To help ensure both patient safety and confidence in the nation's drug supply, it's important to hold all compounded sterile preparations made in the U.S. to a consistent set of quality standards, while avoiding potentially dangerous loopholes."
CAPS delivers compounded sterile preparations daily, both locally and nationwide, from 25 locations. Included in the comments submitted to the Committee was support for the newly proposed "Compounding Manufacturer" category. CAPS looks forward to further engaging in the dialogue on this important patient safety legislation.
CAPS®, the nation's largest network of outsourcing admixture pharmacies, was pioneered in 1991 to deliver high-quality admixture services and solutions to a dynamic and challenging pharmacy environment. State-licensed and FDA-registered, CAPS pharmacies operate 365 days a year to dispense labeled, patient-specific and anticipatory IV prescriptions. To learn more about CAPS, visit www.capspharmacy.com.
About B. Braun
B. Braun Medical Inc. (B.Braun), a leader in infusion therapy and pain management, develops, manufactures, and markets innovative medical products and services to the healthcare industry. The Company is committed to eliminating preventable treatment errors and enhancing patient, clinician an
|SOURCE Central Admixture Pharmacy Services, Inc. (CAPS®), a B. Braun company|
Copyright©2012 PR Newswire.
All rights reserved